Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-rich plasma + fractional laser therapy (DEKA)
- Development stage
- Unknown
- Lead developer
- DEKA Biosciences
- Modality
- Cell Therapies
- Administration
- Intradermal, Topical
01
Overview
This therapeutic intervention is a combination therapy developed by DEKA S.r.l. for the treatment of atrophic acne scars. It involves the use of autologous platelet-rich plasma (PRP) in conjunction with fractional carbon dioxide (CO2) and Erbium:Glass laser resurfacing. PRP is a patient-derived biologic product concentrated with platelets that release various growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors are critical in the wound healing cascade, promoting fibroblast proliferation, collagen synthesis, and dermal remodeling. The fractional lasers (specifically the SmartXide system) create controlled micro-thermal zones of injury in the skin, which synergize with the regenerative properties of the injected or topically applied PRP to enhance tissue repair and reduce the appearance of deep atrophic scars.
- Brand names
- SmartXide
- Other names
- PRP + fractional laserautologous platelet-rich plasmafractional CO2 laser + Erbium:Glass laser + PRP
Beyond the preview
Go deeper on platelet-rich plasma + fractional laser therapy (DEKA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-rich plasma + fractional laser therapy (DEKA).